General
Preferred name
EXENATIDE
Synonyms
Exenatide acetate ()
Exendin-4 acetate ()
Byetta ()
extenatide ()
Exendin-4 (48-86) amide (acetate) ()
Exenatide Synthetic ()
AC-002993 ()
AC2993A ()
LY2148568 ()
AC002993 ()
AC2993 ()
AC-2993LAR ()
Bydureon bcise ()
AC 2993 ()
AC-2993 ()
DA-3091 ()
AC-2993A ()
Bydureon ()
Exendin 4 ()
LY-2148568 ()
EXENDIN-4 ()
ITCA-650 ()
Bydureon pen ()
P&D ID
PD071714
CAS
914454-01-6
141758-74-9
Tags
available
drug
Approved by
FDA
First approval
2005
Drug indication
Cardiovascular disease
Type-2 diabetes
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
11
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Natural product-based probes and drugs
ReFrame library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
40
Properties
(calculated by RDKit )
Molecular Weight
4184.03
Hydrogen Bond Acceptors
60
Hydrogen Bond Donors
58
Rotatable Bonds
134
Ring Count
9
Aromatic Ring Count
5
cLogP
-20.6
TPSA
1749.75
Fraction CSP3
0.61
Chiral centers
37.0
Largest ring
6.0
QED
0.01
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Target
GLP-1
GLP1R
Indication
diabetes mellitus
MOA
GLP receptor agonist
Biosynthetic Origin
Peptide (Ribosomal)
Therapeutic Indication
Antidiabetic
Therapeutic Class
Metabolic Disorders
Hypoglycemic Agents
Source data
